To gain insight into the relationship between DLK1-MEG3 imprinted gene expression and AML patient outcomes, we probed DLK1 and MEG3 expression in AML MNCs and found no significant differences in the expression of these genes based on IR (Fig. 2b). This evidence concerns the gene MEG3 and acute myeloid leukemia.